Long-term results (10 years) of a prospective trial comparing Lo-tact-1 monoclonal antibody and anti-thymocyte globulin induction therapy in kidney transplantation

Transplant International

Volumn 19, Issue 10, 2006, Pages 814-820

  Beaudreuil, S ^a,b   Durrbach, A ^a,b   Noury, J ^c   Ducot, B ^a   Kriaa, F ^a   Bazin, H ^c   Charpentier, B ^a,b  

^a BICÊTRE HOSPITAL   (France)

^b HÔPITAL PAUL BROUSSE   (France)

^c CNRS   (France)

Author keywords

Anti IL2 receptor antibody; Chronic rejection; Renal transplantation

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; LO TACT 1 MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; STEROID; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL INFECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DEMOGRAPHY; FEMALE; FOLLOW UP; GRAFT SURVIVAL; HUMAN; HUMAN CELL; HUMAN TISSUE; INCIDENCE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS INFECTION;

ADULT; ANIMALS; ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RATS; TIME FACTORS;

EID: 33748488230     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2006.00357.x     Document Type: Article

References (27)

1. Webster AC, Playford EG, Higgins G, Chapman JR, Craig JC. Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation 2004; 77: 166.
2. Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet 1997; 350: 1193.
3. Lebranchu Y, Bridoux F, Buchler M, et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2002; 2: 48.
4. Abou-Jaoude MM, Ghantous I, Najm R, Afif C, Almawi WY. Daclizumab versus anti-thymocyte globulin-fresenius as induction therapy for low-risk kidney transplant recipients. Transplant Proc 2003; 35: 2731.
5. Nashan B, Light S, Hardie IR, Lin A, Johnson JR. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. Transplantation 1999; 67: 110.
6. Bumgardner GL, Hardie I, Johnson RW, et al. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation. Transplantation 2001; 72: 839.
7. Kovarik JM, Rawlings E, Sweny P, et al. Pharmacokinetics and immunodynamics of chimeric IL-2 receptor monoclonal antibody SDZ CHI 621 in renal allograft recipients. Transpl Int 1996; 9 (Suppl. 1): S32.
8. Sollinger H, Kaplan B, Pescovitz MD, et al. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection. Transplantation 2001; 72: 1915.
9. Hourmant M, Le Mauff B, Cantarovich D, et al. Prevention of acute rejection episodes with an anti-interleukin 2 receptor monoclonal antibody. II. Results after a second kidney transplantation. Transplantation 1994; 57: 204.
10. Reding R, Vraux H, de Ville de Goyet J, et al. Monoclonal antibodies in prophylactic immunosuppression after liver transplantation. A randomized controlled trial comparing OKT3 and anti-IL-2 receptor monoclonal antibody LO-Tact-1. Transplantation 1993; 55: 534.
11. Hiesse C, Kriaa F, Alard P, et al. Prophylactic use of the IL-2 receptor-specific monoclonal antibody LO-Tact-1 with cyclosporin A and steroids in renal transplantation. Transpl Int 1992; 5 (Suppl. 1): S444.
12. Sayegh MH, Carpenter CB. Tolerance and chronic rejection. Kidney Int Suppl 1997; 58: S11.
13. Wabbijn M, Balk AH, van Domburg RT, et al. Ten-year follow-up of recipients of a kidney or heart transplant who received induction therapy with a monoclonal antibody against the interleukin-2 receptor. Exp Clin Transplant 2004; 2: 201.
14. Rosas SE, Mensah K, Weinstein RB, Bellamy SL, Rader DJ. Coronary artery calcification in renal transplant recipients. Am J Transplant 2005; 5: 1942.
15. Ojo AO, Hanson JA, Wolfe RA, Leichtman AB, Agodoa LY, Port FK. Long-term survival in renal transplant recipients with graft function. Kidney Int 2000; 57: 307.
16. Briggs JD. Causes of death after renal transplantation. Nephrol Dial Transplant 2001; 16: 1545.
17. Massy ZA, Guijarro C, Wiederkehr MR, Ma JZ, Kasiske BL. Chronic renal allograft rejection: immunologic and nonimmunologic risk factors. Kidney Int 1996; 49: 518.
18. Solez K, Vincenti F, Filo RS. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tarolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group. Transplantation 1998; 66: 1736.
19. Baan CC, van Riemsdijk-Overbeeke IC, Boelaars-van Haperen MJ, Jm IJ, Weimar W. Inhibition of the IL-15 pathway in anti-CD25 mAb treated renal allograft recipients. Transpl Immunol 2002; 10: 81.
20. Weimer R, Staak A, Susal C, et al. ATG induction therapy: long-term effects on Th1 but not on Th2 responses. Transpl Int 2005; 18: 226.
21. Gulanikar AC, MacDonald AS, Sungurtekin U, Belitsky P. The incidence and impact of early rejection episodes on graft outcome in recipients of first cadaver kidney transplants. Transplantation 1992; 53: 323.
22. Basadonna GP, Matas AJ, Gillingham KJ, et al. Early versus late acute renal allograft rejection: impact on chronic rejection. Transplantation 1993; 55: 993.
23. Matas AJ, Humar A, Payne WD, et al. Decreased acute rejection in kidney transplant recipients is associated with decreased chronic rejection. Ann Surg 1999; 230: 493.
24. Amlot PL, Rawlings E, Fernando ON, et al. Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. Transplantation 1995; 60: 748.
25. Hale G, Clark M, Waldmann H. Therapeutic potential of rat monoclonal antibodies: isotype specificity of antibody-dependent cell-mediated cytotoxicity with human lymphocytes. J Immunol 1985; 134: 3056.
26. Ritz J, Schlossman SF. Utilization of monoclonal antibodies in the treatment of leukemia and lymphoma. Blood 1982; 59: 1.
27. Hughes-Jones NC, Gorick BD, Howard JC. The mechanism of synergistic complement-mediated lysis of rat red cells by monoclonal IgG antibodies. Eur J Immunol 1983; 13: 635.